Contact:Simon Castellanos877.443.4006 FOR IMMEDIATE RELEASEMarch 16, 2020 COVID-19 response: AIS Healthcare continues to go above and beyond to protect patients and support providers In addition to our industry-leading safety and quality standards across all three of our care divisions, AIS Healthcare is implementing additional measures in response to COVID-19. Dallas, Texas—AIS Healthcare is committed to […]
The acquisition marks AIS Healthcare’s expansion into ophthalmology and a continuation of its commitment to providing patient-specific medication of the highest quality.
AIS Healthcare is proud to announce that its two state-of-the-art 503A compounding pharmacies and its four Advanced Infusion Care locations have received the prestigious URAC accreditation in Specialty Pharmacy, and its Dallas-based Care Coordination Program has been awarded URAC accreditation for Health Call Center.
AIS Healthcare opened its second 503A specialty compounding pharmacy in Dallas, creating a fully redundant targeted drug delivery operation that goes beyond state and industry standards to produce medications of the highest quality.
The recently released 20% subcutaneous immunoglobulin therapy expands treatment options offered by Advanced Infusion Care.
As the designated 503A provider with Premier, AIS Healthcare will offer its TDD pump medications to Premier’s alliance of 4,000 U.S. hospitals and 165,000 other providers.
Chief Medical Officer Anish S. Patel, MD, MBA, will continue to advance AIS Healthcare’s clinical and quality agenda, working to improve patient outcomes and therapy development.